Phosphonic acid derivatives as inhibitors of protein...

Details Phosphonic acid derivatives as inhibitors of protein... Phosphonic acid derivatives as inhibitors of protein...

2000-12-21

2002-11-26

Gerstl, Robert (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S092000, C514S125000, C548S113000, C548S119000, C558S198000, C562S023000, C562S024000, C562S025000

Reexamination Certificate

active

06486142

ABSTRACT:

BACKGROUND OF THE INVENTION
This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B.
Protein tyrosine phosphatases are a large family of transmembrane or intracellular enzymes that dephosphorylate substrates involved in a variety of regulatory processes (Fischer et al., 1991, Science 253:401-406). Protein tyrosine phosphatase-1B (PTP-1B) is a ~50 kd intracellular protein present in abundant amounts in various human tissues (Charbonneau et al., 1989, Proc. Natl. Acad. Sci. USA 86:5252-5256; Goldstein, 1993, Receptor 3:1-15).
Determining which proteins are substrates of PTP-1B has been of considerable interest. One substrate which has aroused especial interest is the insulin receptor. The binding of insulin to its receptor results in autophosphorylation of the receptor, most notably on tyrosines 1146, 1150, and 1151 in the kinase catalytic domain (White & Kahn, 1994, J. Biol. Chem. 269:1-4). This causes activation of the insulin receptor tyrosine kinase, which phosphorylates the various insulin receptor substrate (IRS) proteins that propagate the insulin signaling event further downstream to mediate insulin's various biological effects.
Seely et al., 1996, Diabetes 45:1379-1385 (“Seely”) studied the relationship of PTP-1B and the insulin receptor in vitro. Seely constructed a glutathione S-transferase (GST) fusion protein of PTP-1B that had a point mutation in the PTP-1B catalytic domain. Although catalytically inactive, this fusion protein was able to bind to the insulin receptor, as demonstrated by its ability to precipitate the insulin receptor from purified receptor preparations and from whole cell lysates derived from cells expressing the insulin receptor.
Ahmad et al., 1995, J. Biol. Chem. 270:20503-20508 used osmotic loading to introduce PTP-1B neutralizing antibodies into rat KRC-7 hepatoma cells. The presence of the antibody in the cells resulted in an increase of 42% and 38%, respectively, in insulin stimulated DNA synthesis and phosphatidyinositol 3′ kinase activity. Insulin receptor autophosphorylation and insulin receptor substrate-1 tyrosine phosphorylation were increased 2.2 and 2.0-fold, respectively, in the antibody-loaded cells. The antibody-loaded cells also showed a 57% increase in insulin stimulated insulin receptor kinase activity toward exogenous peptide substrates.
Recently, Kennedy et al., 1999, Science 283: 1544-1548 showed that protein tyrosine phosphatase PTP-1B is a negative regulator of the insulin signalling pathway, suggesting that inhibitors of this enzyme may be beneficial in the treatment of Type 2 diabetes. Mice lacking PTP-1B are resistant to both diabetes and obesity.
Thus, inhibitors of PTP-1B improve insulin-sensitivity. They have utility in controlling or treating Type 1 and Type 2 diabetes, in improving glucose tolerance, and in improving insulin sensitivity in patients in need thereof. The compounds may also be useful in treating or preventing cancer, neurodegenerative diseases and the like.
SUMMARY OF THE INVENTION
Compounds represented by Formula I, and pharmaceutically acceptable salts thereof, and prodrugs thereof, are PTP-1B inhibitors and are useful in the treatment of diabetes, obesity and related conditions.
In the compounds having Formula I, R
1
and R
2
are selected from the group consisting of:
C
1-10
alkyl(R
a
)
0-7
, C
2-10
alkenyl(R
a
)
0-7
, Aryl(R
a
)
0-3
and Het(R
a
)
0-3
;
wherein, each R
a
independently represents a member selected from the group consisting of: Aryl, OH, CN, halogen, CO
2
H, CO
2
C
1-6
alkyl, OC
1-6
alkyl, C
1-6
alkyl, OC
1-10
alkyleneCO
2
H, O Aryl, C
0-6
alkyleneSO
3
H, C
0-6
alkyleneCO
2
H, C
0-6
alkyleneCO
2
C
1-6
alkyl, C
0-6
alkyleneCO
2
C
2-6
alkenyl, C
0-6
alkyleneC(O)C
1-6
alkyl, C(O)NR
3′
R
4′
, NR
3′
R
4′
, C
1-6
haloalkyl, OC
1-6
haloalkyl, S(O)
Y
C
1-6
alkyl, S(O)
y
NR
3′
R
4′
, and Het, wherein y is 0, 1, or 2, wherein Het, Aryl, alkyl, and alkenyl in R
a
are optionally substituted with 1-3 substituents independently selected from halogen, C
1-6
alkyl, C
1-6
haloalkyl, CO
2
H, CO
2
C
1-6
alkyl, OC
1-10
alkyl, OH, Het and Aryl, where said Het and Aryl are optionally substituted with 1-2 substituents independently selected from halogen, C
1-3
alkyl, OC
1-3
alkyl, CF
3
, and OCF
3
;
Aryl is a 6-14 membered carbocyclic aromatic ring system comprising 1-3 phenyl rings, wherein said rings are fused together so that adjacent rings share a common side when there is more than one aromatic ring;
Het represents a 5-10 membered aromatic ring system comprising one ring or two fused rings, 1-4 heteroatoms, 0-4 of which are N atoms and 0-2 of which are O or S(O)
y
wherein y is 0-2, and 0-2 carbonyl groups;
Y, Z
1
and Z
2
each independently represent —(CR
3
R
4
)
a
—X—(CR
3
R
4
)
b
— wherein a and b are either 0 or 1, such that the sum of a and b equals 0, 1 or 2;
X represents a bond, O, S(O)
y
, NR
3′
, C(O), OC(O), C(O)O, C(O)NR
3′
, NR
3′
C(O) or —CH═CH—, where y is as previously defined;
R
3
and R
4
are independently H, halo, C
1-3
alkyl, or C
1-3
haloalkyl;
each R
3′
is independently selected from the group consisting of: H, C
1-6
alkyl, C
1-6
haloalkyl, OH, C(O)C
1-6
alkyl, C(O)Aryl, C(O)Het, C(O)C
1-6
haloalkyl, Aryl and Het;
each R
4′
is independently selected from the group consisting of: H, C
1-6
alkyl, C
1-6
haloalkyl, Aryl and Het; and
each W
1
is independently selected from the group consisting of: H, OH, CN, halogen, OC
1-6
alkyl(R
a
)
0-3
, S(O)
y
C
1-6
alkyl(R
a
)
0-3
, with y equal to 0-2, S(O)
3
H, C
1-6
alkyl(R
a
)
0-3
, C
1-6
haloalkyl(R
a
)
0-3
, CO
2
H, CO
2
C
1-6
alkyl(R
a
)
0-3
, CO
2
C
1-6
haloalkyl(R
a
)
0-3
, CO
2
C
2-6
alkenyl(R
a
)
0-3
, C(O)C
1-6
alkyl(R
a
)
0-3
, C(O)NR
3
′R
4′
, S(O)
y
NR
3′
R
4′
, NR
3′
R
4′
, Aryl and Het, wherein R
3′
and R
4′
are as defined above, and wherein Aryl and Het may be unsubstituted or are optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C
1-6
alkyl, C
1-6
haloalkyl, CO
2
H, CO
2
C
1-6
alkyl, OC
1-6
alkyl, OC
1-6
haloalkyl, and OH; or the two W
1
groups are on adjacent positions of the aromatic ring and are taken in combination to represent a fused phenyl ring.
Methods of treating, controlling and preventing diabetes, obesity, and other related diseases and conditions using the compounds of Formula I are taught herein. Pharmaceutical compositions and combination therapies are also disclosed herein.
DETAILED DESCRIPTION OF THE INVENTION
In a subset of compounds of Formula I, each W
1
represents H or halogen. In a preferred subset of these compounds, one W
1
group represents H and the other W
1
group represents a halogen in the position adjacent to —CF
2
P(O)(OH)
2
on the aromatic ring.
In a subset of any of the groups of compounds above, each Het is selected from the group consisting of pyridinyl, 1H-1,2,3-benzotriazolyl, 1,2,4-oxadiazolyl and 1,3-thiazolyl.
In one embodiment of this invention, Y is —CH
2
—.
In another embodiment of compounds in accordance with claim
1
, Z
1
and Z
2
are each independently selected from the group consisting of CH
2
, —C(O)—, and a direct bond.
Another embodiment comprises compounds in which R
1
and R
2
are each independently selected from the group consisting of Aryl(R
a
)
0-3
and Het(R
a
)
0-3
.
In another embodiment, R
1
and R
2
of Formula I are each independently selected from the group consisting of
(a) (CH
2
)
0-3
phenyl, which is optionally mono, di-, or trisubstituted, wherein the substituents are selected from the group consisting of:
(1) halo,
(2) C
1-6
alkoxy,
(3) C
1-6
alkylthio,
(4) C
1-6
alkyl,
(5) C
1-6
fluoroalkyl,
(6) —CO
2
H,
(7) —CO
2
—C
1-4
alkyl,
(8) —CO
2
C
1-4
fluoroalkyl,
(9) heteroaryl, which is optionally mono, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of halogen, C
1-6
alkoxy, C
1-6
alkylthio, C
1
-C
6
fluoroalkyl, C
1-6
alkyl, —CO
2
H, —CO
2
C
1-4
alkyl, —CO
2
C
1-4

Affiliated with

Also associated with

Rating

Phosphonic acid derivatives as inhibitors of protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphonic acid derivatives as inhibitors of protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphonic acid derivatives as inhibitors of protein... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2925381